Qsymia Side Effects (2026): What's Common, What's Serious & How to Manage Them

The most common Qsymia side effects are paresthesia (tingling, usually in the hands and feet), dizziness, dysgeusia (an altered or metallic taste), insomnia, constipation, and dry mouth — most of them driven by the topiramate half of the drug, with the phentermine half adding stimulant effects like a faster heart rate and trouble sleeping.^[1] Qsymia is phentermine plus topiramate extended-release, an oral once-daily combination capsule — it is not a GLP-1 and works by a completely different mechanism than Ozempic, Wegovy, or Zepbound. The most serious concern is teratogenicity: topiramate raises the risk of oral clefts (cleft lip and cleft palate) in babies exposed in the first trimester, so Qsymia is dispensed through a restricted REMS program and is contraindicated in pregnancy.^[1] This guide separates what is common and expected from what is rare and serious, explains why each effect happens, and lays out exactly when to call your prescriber. This is general educational information, not medical advice — your prescriber manages your care.

The most common side effects

In the placebo-controlled phase 3 trials summarized in the FDA label §6, the reactions reported most often with Qsymia were paresthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.^[1] These are generally mild to moderate, are dose-related (more frequent at the higher 11.25/69 mg and 15/92 mg titration steps), and are the reason Qsymia is started low and stepped up slowly.

• Paresthesia (tingling). A "pins and needles" or tingling sensation, classically in the hands, feet, and around the mouth — one of the most characteristic and common Qsymia effects, driven by topiramate. Usually not dangerous, but persistent or bothersome tingling is worth raising with your prescriber.^[1]
• Dizziness. Common; can contribute to falls in older patients, so stand up slowly and avoid driving until you know how Qsymia affects you.^[1]
• Dysgeusia (altered taste). A change in how things taste — often a metallic taste, or carbonated drinks tasting "flat" or unpleasant. A well-known topiramate effect; usually reversible.^[1]
• Insomnia. Trouble falling or staying asleep, driven mainly by the stimulant phentermine component — one reason Qsymia is taken in the morning rather than later in the day.^[1]
• Constipation. Common; the flip side of reduced appetite and lower food/fluid intake, manageable with fluids and fiber.^[1]
• Dry mouth. A frequent, generally mild effect of both components; sipping water and sugar-free gum or lozenges help.^[1]

Other reactions reported more often than with placebo include upper respiratory tract infection, headache, fatigue, irritability, blurred vision, and decreased appetite — the last of which, for a weight-management medication, is partly the intended effect rather than a true adverse event.^[1] The table and chart below put the headline rates side by side against placebo so you can see how much of each is drug-attributable.

Why they happen — the two mechanisms, plus titration

Qsymia is a fixed-dose combination of two different drugs, so its side effects come from two different directions — and knowing which component drives which effect helps make sense of them.

• Topiramate (the "-topiramate ER" half) is an anticonvulsant repurposed for weight management. It drives the paresthesia (tingling), dysgeusia (taste changes), cognitive and concentration effects, metabolic acidosis, and the kidney-stone and glaucoma risks. The tingling, in particular, is a hallmark topiramate effect related to its inhibition of carbonic anhydrase.^[1]
• Phentermine (the "phentermine-" half) is a sympathomimetic appetite suppressant — a stimulant. It drives the increased heart rate, insomnia, dry mouth, and irritability/agitation, and is the reason Qsymia is dosed in the morning to limit sleep disruption.^[1]

Because both components' effects scale with dose, Qsymia is titrated slowly. The label starts every patient at 3.75/23 mg once daily in the morning for 14 days, then steps up to the recommended 7.5/46 mg; if more weight loss is needed and the dose is tolerated, it escalates to 11.25/69 mg for 14 days and then the maximum 15/92 mg once daily.^[1] Starting low and climbing gradually lets the body adapt and keeps the tingling, taste changes, and dizziness more manageable. The label also notes that Qsymia should not be stopped abruptly at the higher doses — discontinuation is tapered to reduce the risk of seizures tied to the topiramate component. For the dosing context and how Qsymia compares with plain phentermine products, see our guide to getting phentermine prescribed online.

Serious but less common side effects

Beyond the common reactions, the Qsymia label §4-§5 lists several serious but less common risks. These are uncommon, but each warrants awareness because some require stopping the drug and seeking care. The first one — teratogenicity — is the single most important reason Qsymia is a restricted, REMS-gated, prescription-only medication.

• Teratogenicity — fetal oral clefts (the major one). Topiramate increases the risk of cleft lip and cleft palate when a fetus is exposed in the first trimester, often before a person knows they are pregnant. This is why Qsymia is contraindicated in pregnancy, distributed only through a restricted REMS program, and paired with pregnancy testing and effective contraception. This risk is covered in full in the dedicated section below.^[1]
• Increased heart rate. The phentermine component can raise resting heart rate; the label advises monitoring heart rate in all patients, especially those with cardiac or cerebrovascular disease. Report a racing or pounding heartbeat, especially at rest, to your prescriber.^[1]
• Mood disorders and suicidal behavior/ideation. Topiramate-containing products carry a signal for depression and suicidal thoughts or behavior. Watch for new or worsening depression, anxiety, or any thoughts of self-harm, and report them promptly; Qsymia is generally not recommended in patients with a history of severe depression or suicidality.^[1]
• Metabolic acidosis. Topiramate can lower blood bicarbonate (a non-anion-gap, hyperchloremic metabolic acidosis). Chronic acidosis can contribute to kidney stones and bone effects; prescribers may check bicarbonate before and during treatment. Symptoms can include fatigue, loss of appetite, and rapid breathing.^[1]
• Acute angle-closure glaucoma. A rare but urgent topiramate effect: sudden eye pain, redness, and blurred vision from a rapid rise in eye pressure, typically within the first month. This is a medical emergency — untreated it can cause permanent vision loss.^[1]
• Cognitive and concentration effects. Topiramate can cause trouble with concentration, attention, memory, and word-finding, along with confusion or "brain fog." These are dose-related and usually reversible; report them, as the dose may need to be adjusted.^[1]
• Kidney stones (nephrolithiasis). Topiramate raises the risk of kidney stones, partly through carbonic-anhydrase inhibition and acidosis. Staying well-hydrated lowers the risk; report flank or back pain and blood in the urine.^[1]
• Other label warnings. The label also notes the potential for elevated creatinine, mood/sleep disturbances, a small drop in body temperature/oligohidrosis (decreased sweating, more relevant in children and hot weather), and — like other antiepileptics — caution against abrupt discontinuation because of seizure risk.^[1]

The REMS, the pregnancy contraindication, and birth control

Qsymia's single most important safety feature is its pregnancy contraindication and the restricted REMS program built around it. In two large databases, the topiramate component was associated with an increased prevalence of oral clefts (cleft lip with or without cleft palate) in infants exposed during the first trimester — a window when many pregnancies are not yet recognized.^[1]

Because of that, the label requires a structured set of safeguards for patients who can become pregnant:

• Negative pregnancy test before starting Qsymia, and monthly pregnancy tests during treatment.^[1]
• Effective contraception throughout treatment. Patients should also be counseled that topiramate can interact with some hormonal contraceptives; this is a point to confirm with the prescriber when choosing a birth-control method.^[1]
• Dispensing only through REMS-certified pharmacies, with education materials and a Medication Guide provided to the patient.^[1]
• Stop Qsymia and call the prescriber immediately if pregnancy occurs or is suspected.^[1]

This is the same teratogenicity-driven REMS structure discussed in our broader guide on how phentermine and Qsymia are prescribed online — and it is the reason Qsymia is harder to obtain through telehealth than plain generic phentermine: not every pharmacy is REMS-certified, and the monthly pregnancy testing has to actually be built into care. A platform that offers "Qsymia online" without addressing the REMS is a red flag.

How to manage the common side effects

Most of the common Qsymia effects are manageable, and the strategies work with the slow-titration design rather than against it. The following are general, commonly-discussed approaches — all of them are prescriber-directed, and you should not change your dose, add medications, or stop Qsymia without talking to your clinician (and Qsymia at higher doses should be tapered, not stopped abruptly).

• Respect the titration schedule. Tingling, taste changes, and dizziness are usually heaviest after a step-up and ease as the body adapts. If a rung is rough, your prescriber can hold you at the current dose longer rather than escalating.^[1]
• Take it in the morning. The phentermine component drives insomnia, so the label dosing is once daily in the morning — taking it late predictably worsens sleep.^[1]
• Stay well-hydrated. Fluids help with dry mouth and constipation and genuinely lower the risk of kidney stones tied to topiramate — so this is a safety measure, not just comfort.^[1]
• Manage dry mouth and taste changes. Sip water, use sugar-free gum or lozenges, and know that the metallic/"flat" taste (including carbonated drinks tasting off) is a known topiramate effect that usually reverses.
• Manage constipation actively. Adequate fluids, dietary fiber, and movement help; your prescriber may suggest an over-the-counter option.
• Flag any cognitive or mood changes early. Trouble concentrating, word-finding difficulty, low mood, or anxiety should be reported, not pushed through — the dose may need adjusting, and the mood signal is a genuine safety item.^[1]

If you are weighing Qsymia against other options under proper medical supervision, see the FDA-approved weight loss medications hub, or — for the injectable/GLP-1 route, which has a very different (gut-centered) side-effect profile — compare the best semaglutide providers and read our reviews of Found and Ro.

When to call your provider — or seek urgent care

Most Qsymia side effects are mild and self-limiting, but a defined set of symptoms means contact your prescriber promptly, and some mean seek urgent/emergency care. Use this as a general guide, not a substitute for your clinician's instructions, and when in doubt, call.

• Stop Qsymia and call your prescriber immediately if you become pregnant or think you might be — the topiramate oral-cleft risk is the reason the drug is contraindicated in pregnancy.^[1]
• Seek urgent eye care for sudden eye pain, redness, or blurred vision — possible acute angle-closure glaucoma, which can permanently damage vision if untreated.^[1]
• Seek care for new or worsening depression, anxiety, or any thoughts of self-harm — the mood/suicidality signal — and tell your prescriber right away.^[1]
• Call your prescriber for a racing or pounding heartbeat (especially at rest), which can reflect the phentermine-driven increased heart rate.^[1]
• Call your prescriber for symptoms that could signal metabolic acidosis (unusual fatigue, loss of appetite, rapid breathing) or kidney stones (flank/back pain, blood in the urine).^[1]
• Do not stop Qsymia abruptly at the higher doses on your own — discontinuation should be tapered under your prescriber's direction to reduce seizure risk.^[1]

A legitimate Qsymia prescriber screens you for the pregnancy contraindication and the cardiovascular, glaucoma, and mood histories above, dispenses through a REMS-certified pharmacy, titrates you on the label schedule, and follows up on side effects — exactly the monitoring that keeps Qsymia's risk profile manageable.